Further study showed that the pathological types of CA125 negative patients were mostly non-serous ovarian adenocarcinoma, indicating GDF15 could complement the application of CA125 in those non-serous pathological types. The gene discussed is GDF15; the disease is ovarian serous adenocarcinoma.